Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus

28 August 2023 (15:15 - 15:50)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Professor Yong-Seog Oh

The Catholic University of Korea, Seoul (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail

Effects of SGLT2i on reducing risks of cardiovascular events and dementia in atrial fibrillation patients with diabetes mellitus: a nationwide cohort study

Assistant Professor Y. Chen (Taichung, TW)

Abstract Slides Video

Presentation thumbnail

Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials

Doctor R. Kani (Kamogawa, JP)

Abstract Slides Video

Presentation thumbnail

GLP1-RA versus metformin as first-line therapy for achieving glycemic control and risk-factor management - a one-year nationwide cohort study

Ms K. Soerensen (Copenhagen, DK)

Abstract Slides Video

Presentation thumbnail

The renal outcome post contrast exposure in patient with diabetes and SGLT2 inhibitor

Doctor C. Chen (Taipei, TW)

Abstract Slides Video

Presentation thumbnail

Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset hip fracture risks in patients with type-2 diabetes: A propensity sc

Professor G. Tse (Hong Kong, CN)

Abstract Slides Video

Access the full session

Session thumbnail

Antidiabetic medications and cardiovascular disease

The Event

Event poster

ESC Congress 2023

28 August 2023 15:15 CET

You may be interested in

Congress Session

Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

Congress Presentation

Antithrombotic therapy in diabetes

Congress Session

2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes